This website is intended for UK healthcare professionals only Log in | Register

Tag Archives: CytoSorb®

June 2021 Br J Cardiol 2021;28:67–9 doi:10.5837/bjc.2021.026

Reducing antithrombotic-related bleeding risk in urgent and emergency cardiac surgery

Amer Harky, Abdul Badran

Abstract

Introduction Bleeding post cardiac surgery carries significant patient mortality and morbidity including resternotomy, increased hospital stays, and blood product transfusion.1,2 Bleeding is more severe in patients who are taking pre-operative antiplatelet or anticoagulation medications that have not been stopped sufficiently in advance to minimise such risks. Current guidelines across Europe recommend stopping such agents at least two to five days prior to surgery; they also recommend delaying urgent surgery so that the risk of perioperative bleeding is minimised.3 However, this is not always possible in the setting of urgent and emergency c

| Full text

February 2019 Br J Cardiol 2019;26:10

Cytokine removal in sepsis and endocarditis

BJC Staff

Abstract

The technology is already used to treat inflammation in critically ill and cardiac surgery patients as an early standalone (I.e. without combined renal replacement) therapy for extracorporeal cytokine removal. It is designed to reduce the ‘cytokine storm’ or ‘cytokine release syndrome’, a major contributing factor in inflammation. The controlled study of 20 patients was conducted by a team at the Department of Anesthesiology and Intensive Therapy of the University Szeged in Hungary, led by Professor Zsolt Molnar. They investigated the effects of a single treatment of extracorporeal cytokine removal with CytoSorb® therapy, in additio

| Full text
Close

You are not logged in

You need to be a member to print this page.
Find out more about our membership benefits

Register Now Already a member? Login now
Close

You are not logged in

You need to be a member to download PDF's.
Find out more about our membership benefits

Register Now Already a member? Login now